Inventiva’s Preclinical Study: Lanifibranor’s Promise in Reducing Portal Hypertension
Daix, France and New York City, February 26, 2025
In a groundbreaking development, Inventiva, a clinical-stage biopharmaceutical company, unveiled the findings of a preclinical study that showcased the potential of lanifibranor in reducing Portal Hypertension (PH). This study, published in the esteemed scientific journal, Biomedicine & Pharmacotherapy, has piqued the interest of researchers and medical professionals worldwide.
The Preclinical Study: An In-Depth Look
In the study, researchers explored the effects of lanifibranor on PH in rodents. Portal hypertension is a serious condition characterized by increased blood pressure in the portal vein, leading to various complications, such as liver damage and even liver failure. The study revealed that lanifibranor, an oral small molecule therapy, effectively decreased the occurrence of PH in the rodents, thus offering a potential treatment option for this debilitating condition.
Lanifibranor: An Overview
Lanifibranor is a first-in-class, selective PPARδ modulator, and a key asset in Inventiva’s pipeline. PPARδ is a nuclear receptor that plays a crucial role in the regulation of various metabolic processes, including lipid metabolism, inflammation, and fibrosis. By modulating PPARδ, lanifibranor exhibits potential therapeutic benefits for a wide range of metabolic diseases, including MASH (metabolic dysfunction-associated steatohepatitis), a severe form of non-alcoholic fatty liver disease.
The Impact on Patients: A New Hope
The potential of lanifibranor in reducing PH could bring new hope to the millions of patients suffering from this condition. Portal hypertension is often a complication of liver cirrhosis, a chronic condition that affects an estimated 2 million people in the United States alone. Currently, there are limited treatment options for PH, making the discovery of lanifibranor’s potential benefits a significant step forward in the medical community.
The Global Impact: A New Era in PH Treatment
The potential impact of lanifibranor on PH treatment extends beyond individual patients. According to the World Health Organization, approximately 11% of the global population is affected by chronic liver diseases, with an estimated 1.34 million deaths each year. The discovery of lanifibranor’s potential in reducing PH could lead to a paradigm shift in the treatment of this condition, ultimately improving the lives of millions of people worldwide.
Conclusion: A Promising Future
The publication of Inventiva’s preclinical study in Biomedicine & Pharmacotherapy marks an exciting moment in the field of PH research. Lanifibranor’s potential to reduce this debilitating condition could lead to a new era in the treatment of portal hypertension, offering hope to the millions of patients affected by this condition. As the study progresses through clinical trials, the medical community eagerly awaits the potential benefits of this first-in-class, selective PPARδ modulator. Stay tuned for further updates on this groundbreaking development.
- Inventiva reveals preclinical study results showing lanifibranor’s potential in reducing portal hypertension.
- Lanifibranor is an oral small molecule therapy and a selective PPARδ modulator.
- Portal hypertension affects approximately 11% of the global population, with an estimated 1.34 million deaths each year.
- The discovery of lanifibranor’s potential benefits could lead to a paradigm shift in the treatment of portal hypertension.
